XNAS · Healthcare · Biotechnology
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | -0.23 | -0.34 | -47.83% | $0 | ❌ Miss | -0.88% | -1.75% | — |
| 2026-03-05 | Q4 2025 | -0.42 | -0.15 | +64.29% | $0 | ✅ Beat | +0.00% | +6.84% | +9.40% |
| 2025-11-13 |
| Q3 2025 |
| -0.44 |
| -0.44 |
| +0.00% |
| $0 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-03-31 | Q4 2024 | -3.60 | -0.85 | +76.39% | $0 | ✅ Beat | -5.38% | -20.77% | +47.69% |
| 2024-11-14 | Q3 2024 | -4.14 | -1.54 | +62.80% | $0 | ✅ Beat | -0.90% | +13.45% | +27.35% |
| 2024-08-14 | Q2 2024 | -0.51 | -3.62 | -609.80% | $0 | ❌ Miss | -1.53% | +17.56% | +25.57% |
| 2024-04-02 | Q4 2023 | -11.70 | -1.53 | +86.92% | $0 | ✅ Beat | +4.46% | +1.49% | +15.78% |
| 2023-08-10 | Q2 2023 | — | -13.23 | — | $0 | — | -1.75% | +0.00% | -3.95% |
Showing last 8 quarters.